Targeted therapies for renal cell carcinoma: more gains from using them again

Por Gan, H.K., Seruga, B., Knox, J.J.
Publicado em 2009

Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

Por Seruga, B., Gan, H.K., Knox, J.J.
Publicado em 2009

In vivo stimulation of a chimeric promoter by binding sites for nuclear factor I.

Por Knox, J J, Rebstein, P J, Manoukian, A, Gronostajski, R M
Publicado em 1991

Smoking: attitudes of Costa Rican physicians and opportunities for intervention.

Por Grossman, D. W., Knox, J. J., Nash, C., Jiménez, J. G.
Publicado em 1999

Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost–consequence analysis

Por Horgan, A.M., Knox, J.J., Liu, G., Sahi, C., Bradbury, P.A., Leighl, N.B.
Publicado em 2011

Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase i study

Por Kassam, Z., MacKay, H., Buckley, C.A., Fung, S., Pintile, M., Oza, A., Brierley, J., Swallow, C., Cummings, B., Knox, J.J., Kim, J., Wong, R., Siu, L., Feld, R., Ringash, J.
Publicado em 2010

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Por Heng, D. Y., MacKenzie, M. J., Vaishampayan, U. N., Bjarnason, G. A., Knox, J. J., Tan, M. H., Wood, L., Wang, Y., Kollmannsberger, C., North, S., Donskov, F., Rini, B. I., Choueiri, T. K.
Publicado em 2012

Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma

Por Sherman, M., Burak, K., Maroun, J., Metrakos, P., Knox, J.J., Myers, R.P., Guindi, M., Porter, G., Kachura, J.R., Rasuli, P., Gill, S., Ghali, P., Chaudhury, P., Siddiqui, J., Valenti, D., Weiss, A., Wong, R.
Publicado em 2011

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Por Leibowitz-Amit, R., Templeton, A. J., Omlin, A., Pezaro, C., Atenafu, E. G., Keizman, D., Vera-Badillo, F., Seah, J.-A., Attard, G., Knox, J. J., Sridhar, S. S., Tannock, I. F., de Bono, J. S., Joshua, A. M.
Publicado no Ann Oncol (2014)

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Por Heng, D. Y. C., Choueiri, T. K., Rini, B. I., Lee, J., Yuasa, T., Pal, S. K., Srinivas, S., Bjarnason, G. A., Knox, J. J., MacKenzie, M., Vaishampayan, U. N., Tan, M. H., Rha, S. Y., Donskov, F., Agarwal, N., Kollmannsberger, C., North, S., Wood, L. A.
Publicado em 2014

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Por Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., Motzer, R. J.
Publicado no Ann Oncol (2017)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

Por Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C
Publicado em 2014